Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2016-08-09 Interim / Quarterly Rep…
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report Q2 2016
2016-08-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is a Regulation FD Disclosure with an attached press release (Exhibit 99.1). The document is short (2619 characters) and primarily serves to furnish information rather than provide detailed financial data or a full report. It does not contain financial statements or detailed analysis but rather a press release disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-08-02 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the departure or retention agreements of certain officers, including retention bonus agreements for the CFO and COO. This fits the category of announcements related to changes in senior management or board members. The document is not a full financial report, earnings release, or other types of filings. Therefore, it is best classified as Board/Management Information (MANG). The document length is 3048 characters, which is typical for an 8-K filing of this nature and not a report publication announcement or regulatory filing fallback. Confidence is high due to clear mention of management retention agreements and the nature of Form 8-K Item 5.02.
2016-06-20 English
Regulatory Filings 2016
Regulatory Filings
2016-05-27 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is a Regulation FD Disclosure with an attached press release (Exhibit 99.1). The document does not contain detailed financial statements or comprehensive financial data, nor does it present an annual or quarterly report. It is a short filing primarily announcing a press release, which fits the definition of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories. The document length is 2633 characters, which is relatively short and consistent with an 8-K filing announcing a press release rather than a full report.
2016-05-16 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce unscheduled material events or corporate changes. The text indicates it is a short filing (2683 characters) that primarily references a press release attached as an exhibit. It states the information is furnished under Item 7.01 Regulation FD Disclosure and explicitly mentions the press release is attached as Exhibit 99.1. There are no financial statements or detailed financial data included in the text. The document is not a full financial report but rather a regulatory announcement of an event or disclosure. According to the rules, such filings that do not contain substantive financial data and serve as announcements or disclosures fall under Regulatory Filings (RNS).
2016-05-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.